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Background: Adiponectin (APN) is an immunomodulatory and cardioprotective adipocytokine that is also expressed in cardiac myocytes. Toll-like 
receptor 4 (TLR4) is essential for the progression of major inflammatory cardiac diseases including autoimmune myocarditis. Here, we investigated if 
APN inhibits cardiac inflammation and injury by interfering with TLR4 signaling.
Methods: APN overexpression in murine experimental autoimmune myocarditis (EAM) was achieved by adenoviral gene transfer. Gene expression 
was analyzed by qRT-PCR and ELISA. NFgB activation was measured by ELISA. Splenocyte migration, dendritic cell (DC) activation and T cell 
proliferation was quantified by FACS. Apoptosis was measured by TUNEL.
Results: APN overexpression in EAM downregulated cardiac expression levels of TLR4 and its major downstream immune response mediators 
TNF_, IL-6, IL-12, CCL2 and ICAM-1 resulting in reduced infiltration of CD3+, CD14+ and CD45+ immune cells and diminished cardiac apoptosis. 
In cardiac myocytes and fibroblasts APN inhibited the induction of a TLR4 mediated inflammatory phenotype by exogenous and endogenous TLR4 
ligands as assessed by attenuated NFgB activation and reduced expression levels of NFgB target genes TNF_, IL-6, CCL2 and ICAM-1. Moreover, 
APN inhibited the TLR4 mediated increase in TNF_ expression in DCs, CD19+ and CD14+ immune cells. Accordingly, splenocytes from APN-/- mice 
showed enhanced expression levels of TNF_, IL-6, IL-12, CCL2 and ICAM-1 after TLR4 ligation. In addition, TLR4 stimulated DCs from APN-/- mice 
displayed decreased ability to induce T cell proliferation. Finally, APN diminished splenocyte migration towards TLR4 activated cardiac myocytes and 
inhibited apoptosis of TLR4 stimulated cardiac myocytes after cocultivation with splenocytes. Mechanistically, APN interfered with TLR4 signaling in 
cardiac myocytes through a COX-2-, PKA- and ERK 1/2- dependent way.
Conclusions: Our observations indicate that APN interferes with TLR4 signaling in cardiac and immune cells thereby protecting against TLR4 
mediated myocardial inflammation and injury in EAM. APN thus represents a promising new option for the therapy of inflammatory cardiac diseases.
